BR112015030644A2 - Composições de peptídeos de sobreposição contígua, bem como peptídeos e seu uso no tratamento de alergia aos ácaros da poeira doméstica - Google Patents

Composições de peptídeos de sobreposição contígua, bem como peptídeos e seu uso no tratamento de alergia aos ácaros da poeira doméstica

Info

Publication number
BR112015030644A2
BR112015030644A2 BR112015030644A BR112015030644A BR112015030644A2 BR 112015030644 A2 BR112015030644 A2 BR 112015030644A2 BR 112015030644 A BR112015030644 A BR 112015030644A BR 112015030644 A BR112015030644 A BR 112015030644A BR 112015030644 A2 BR112015030644 A2 BR 112015030644A2
Authority
BR
Brazil
Prior art keywords
peptides
treatment
allergy
compositions
well
Prior art date
Application number
BR112015030644A
Other languages
English (en)
Inventor
Kettner Alexander
Reymond Christophe
Original Assignee
Anergis S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anergis S A filed Critical Anergis S A
Publication of BR112015030644A2 publication Critical patent/BR112015030644A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

COMPOSIÇÕES DE PEPTÍDEOS DE SOBREPOSIÇÃO CONTÍGUA, BEM COMO PEPTÍDEOS E SEU USO NO TRATAMENTO DE ALERGIA A OS ÁCAROS DA POEIRA DOMÉSTICA. A presente invenção refere-se a composições de peptídeos de sobreposição contígua (COPs) derivados de Der p 1 e Der p 2, bem como peptídeos e seu uso no tratamento de alergia aos ácaros da poeira doméstica. Tais peptídeos fornecem o potencial total dos epítopos da célula T e são desprovidos da estrutura tridimensional do alérgeno original, reduzindo sua capacidade de se ligar a IgE. Como resultado, as quantidades aumentadas de peptídeos de sobreposição podem ser administradas por número reduzido de injeção, e duração do tratamento com imunoterapia.
BR112015030644A 2013-06-06 2014-06-06 Composições de peptídeos de sobreposição contígua, bem como peptídeos e seu uso no tratamento de alergia aos ácaros da poeira doméstica BR112015030644A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831961P 2013-06-06 2013-06-06
PCT/IB2014/001888 WO2014195803A2 (en) 2013-06-06 2014-06-06 Contiguous overlapping peptides for treatment of house dust mites allergy

Publications (1)

Publication Number Publication Date
BR112015030644A2 true BR112015030644A2 (pt) 2017-08-29

Family

ID=51844771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030644A BR112015030644A2 (pt) 2013-06-06 2014-06-06 Composições de peptídeos de sobreposição contígua, bem como peptídeos e seu uso no tratamento de alergia aos ácaros da poeira doméstica

Country Status (12)

Country Link
US (1) US20150050301A1 (pt)
EP (1) EP3003366B1 (pt)
JP (2) JP6300907B2 (pt)
CN (1) CN105307679A (pt)
AU (1) AU2014276484B2 (pt)
BR (1) BR112015030644A2 (pt)
CA (1) CA2914037A1 (pt)
DK (1) DK3003366T3 (pt)
ES (1) ES2828448T3 (pt)
HK (1) HK1223019A1 (pt)
RU (1) RU2015155874A (pt)
WO (1) WO2014195803A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
CN107405394B (zh) 2015-02-20 2021-12-14 斯坦福大学托管董事会 混合变应原组合物及其使用方法
NL2014882B1 (en) 2015-05-29 2017-01-31 Citeq B V Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy.
CN108265056B (zh) 2016-12-31 2019-08-30 江苏众红生物工程创药研究院有限公司 一种重组户尘螨1类变应原蛋白及其制备方法和应用
CN108265057B (zh) * 2016-12-31 2019-10-18 江苏众红生物工程创药研究院有限公司 一种重组户尘螨2类变应原蛋白及其制备方法和应用
US11382934B2 (en) 2017-07-18 2022-07-12 Before Brands, Inc. Methods for making mixed allergen compositions
WO2019216394A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
WO2019242662A1 (zh) * 2018-06-22 2019-12-26 江苏众红生物工程创药研究院有限公司 重组尘螨变应原蛋白药物合剂及其应用
WO2020154476A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100260342B1 (ko) * 1991-10-16 2000-07-01 스타세이 엘. 첸링 더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CZ20031653A3 (en) * 2000-11-16 2004-03-17 Alk-Abelló A/S Mutant allergens
US7923209B2 (en) * 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
CA2696563A1 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptides for vaccine
CA2750705C (en) * 2009-02-09 2015-12-29 Anergis S.A. Contiguous overlapping peptides for treatment of birch pollen allergy
DK2723373T3 (en) * 2011-06-27 2017-09-18 Anergis S A OVERLAPPING ADJUSTING PEPTIDES FOR TREATMENT

Also Published As

Publication number Publication date
WO2014195803A2 (en) 2014-12-11
US20150050301A1 (en) 2015-02-19
JP2018058856A (ja) 2018-04-12
JP2016523231A (ja) 2016-08-08
WO2014195803A3 (en) 2015-05-28
CN105307679A (zh) 2016-02-03
EP3003366A2 (en) 2016-04-13
AU2014276484B2 (en) 2018-01-25
EP3003366B1 (en) 2020-08-05
AU2014276484A1 (en) 2015-12-03
ES2828448T3 (es) 2021-05-26
RU2015155874A (ru) 2017-07-14
CA2914037A1 (en) 2014-12-11
JP6640818B2 (ja) 2020-02-05
DK3003366T3 (da) 2020-10-26
JP6300907B2 (ja) 2018-03-28
HK1223019A1 (zh) 2017-07-21

Similar Documents

Publication Publication Date Title
BR112015030644A2 (pt) Composições de peptídeos de sobreposição contígua, bem como peptídeos e seu uso no tratamento de alergia aos ácaros da poeira doméstica
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA202090593A3 (ru) Пептидное соединение
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
MY172578A (en) Oral dosing of glp-1 compounds
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
DOP2013000280A (es) Proteínas de unión a antígeno
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
EA201791841A1 (ru) Новые белки, специфичные к пиовердину и пиохелину
EA201791186A1 (ru) Антитела к cd38
CL2012002536A1 (es) Composición farmacéutica que comprende un anticuerpo anti-factor de crecimiento nervioso (ngf) o un fragmento de unión al antígeno de éste, un amortiguador histidina 5 a 60mm, polisorbato 80 0,01% a 0,1%, y un ph entre 5,0 y 6,0; composición liofilizada; dispositivo; artículo de manufactura; y su uso en enfermedades mediadas por ngf, tales como trastornos del dolor.
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
PE20140616A1 (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
EA201590342A1 (ru) Лечение иммуноопосредуемых и воспалительных заболеваний
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
NI201500050A (es) Benzamidas
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
CL2015002030A1 (es) Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
BR112015018504A2 (pt) moduladores de flap

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.